Three different procedures in labeling of ubiquicidin with technetium 99m: A comparative study

Iranian Journal of Radiation Research

Volumn 7, Issue 2, 2009, Pages 97-104

  Gandomkar, M ^a   Najafi, R ^a   Mazidi, M ^a   Mirfallah, S H ^a   Goudarzi, M ^a  

^a NUCLEAR SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Iran)

Author keywords

Antimicrobial peptide; Direct labelling; Indirect labelling; Infection

Indexed keywords

6 HYDRAZINOPYRIDINE 3 CARBOXYLIC ACID; CARBOXYLIC ACID DERIVATIVE; ETHYLENEDIAMINE DERIVATIVE; GLYCINE DERIVATIVE; N,N' ETHYLENEDIAMINEDIACETIC ACID; PERTECHNETIC ACID TC 99M; POLYPEPTIDE ANTIBIOTIC AGENT; TECHNETIUM 99M; TIN CHLORIDE; TRICINE; UBIQUICIDIN 29 41; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ARTICLE; BACTERIUM ADHERENCE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG PURITY; DRUG STABILITY; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; RADIOACTIVITY; RADIOISOTOPE DIAGNOSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCINTIGRAPHY; SOLID PHASE SYNTHESIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 77953700405     PISSN: 23223243     EISSN: 17284562     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Welling M, Paulusma-Annema A, Balter H.S, Pauwels E.K.J, Nibbering P.H (2000) Technetium-99m labeled antim-icrobial peptides discriminate between bacterial infec-tions and sterile inflammations. Eur J Nucl Med, 27: 291-301.
2. Welling M, Monguera S, Lupetti A, Balter H.S, Bonetto V, Mazzi U, et al. (2002) Radiochemical and biological characteristics of 99mTc-UBI 29-41 for imaging of bacte-rial infections. Nucl Med Biol, 29: 413-422.
3. Nibbering P.H, Welling M, Broek V.D, Pauwels E.K.J (1998) Radiolabelled antimicrobial peptides for imaging of in-fections: a review. Nucl Med Commun, 19: 1117-1121.
4. Ferro-Flores G, Arteaga de Murphy C, Pedraza-Lopez M, Melendez-Alafort L, Zhang Y.M, Rusckowski M, et al. (2003) In-vitro and in vivo assessment of 99mTc-UBI specificity for bacteria. Nucl Med Biol, 30: 597-603.
5. Welling M.M, Lupetti A, Balter H.S, Lanzzeri S, Souto B, Rey A.M et al. (2001) 99mTclabeled antimicrobial pep-tides for detection of bacterial and Candida albicans infections. J Nucl Med, 42: 788-794.
6. Lupetti A, Welling M.M, Pauwels E.K.J, Nibbering P.H (2003) Radiolabelled antimicrobial peptides for infec-tion detection. Lancet Infect Dis, 3: 223-229.
7. Hiemstra P.S (1993) "Antimicrobial proteins of murine macrophages". Infect Immun, 61: 3038-3046.
8. Hiemstra P.S, et al. (1999) "Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages". J Leukocyte Biol, 66: 423-428.
9. Welling M.M, Visentin R, Feitsma H.I, Lupetti A, Pauwels E.K, Nibbering P.H (2004) Infection detection in mice using 99mTc-labeled HYNIC and N2S2 chelate conju-gated to the antimicrobial peptide UBI 29-41. Nucl Med Biol, 31: 503-509.
10. Welling M.M, Korsak A, Gorska B, Oliver P, Mikolajczak R, Balter H.S, et al. (2005) Kit with technetium-99m labeled antimicrobial peptide UBI 29-41 for specific infection detection. J Label Compd Radiopharm, 48: 683-691.
11. Gandomkar M, Najafi R, Shafiei M, Mazidi M, Ebrahimi S.E.S (2007) Preclinical evaluation of [99mTc/EDDA/ tricine/HYNIC0,1-Nal3, Thr8]-octreotide as a new ana-logue in the detection of somatostatin-receptor-positive tumors. Nucl Med Biol, 34: 651-657.
12. Melendez-Alafort L, Rodriguez-Cortes J, Ferro-Flores G, Arteaga De Murphy C, Herrera-Rodriguez R, Mitsoura E, et al. (2004) Biokinetics of 99mTc-UBI 29-41 in humans. Nucl Med Biol, 31: 373-379.
13. Akhtar M.S, Qaisar A, Irfanullah J, Iqbal J, Khan B, Jehangir M, et al. (2005) Antimicrobial peptide 99mTc-ubiquicidin 29-41 as human infectionimaging agent: clinical trial. J Nucl Med, 46: 567-573.
14. Abrams M.J, Juweid M, tenKate C.I, Schwartz D.A, Hauser M.M, Gaul F.E, et al. (1990) Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med, 31: 2022-2028.
15. Babich J.W and Fischman A.J (1995) Effect of "co-ligand" on the biodistribution of 99mTc-labeled hydrazino nico-tinic acid derivatized chemotactic peptides. Nucl Med Biol, 22: 25-30.
16. Decristoforo C and Mather S.J (1999) Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence. Eur J Nucl Med, 26: 869-876.
17. Rennen H.J.J.M, van Eerd J.E, Oyen W.J.G, Corstens F.H.M, Edwards D.S, Boerman O.C (2002) Effects of coligand variation on the in vivo characteristics of Tc-99m-labeled interleukin-8 in detection of infection. Bioconj Chem, 13: 370-377.
18. Liu S and Edwards D.S. (1999) 99mTc-labeled small pep-tides as diagnostic radiopharmaceuticals. Chem Rev, 99: 2235-2268.
19. Edwards D.S, Liu S, Barrett J.A, Harris A.R, Looby R.J, Ziegler M.C, Heminway S.J, Carroll T.R (1997) New and versatile ternary ligand system for technetium radio-pharmaceuticals: water soluble phosphines and tricine as coligands in labeling a hydrazinonicotinamide-modified cyclic glycoprotein Iib/IIIa receptor antagonist with 99mTc. Bioconj Chem, 8: 146-154.
20. Decristoforo C, Melendez-Alafort L, Sosabowski J.K, Mather S (2000) 99mTc-HYNIC-Tyr3-octreotide for imag-ing somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide. J Nucl Med, 41: 1114-1119.
21. Von Guggenberg E, Behe M, Behr T, Saurer M, Seppi T, Decristoforo C (2004) 99mTc-labeling and in-vitro and in-vivo evaluationof HYNIC-and (Na-His) acetic acid-modified [D-Glu1]-minigastrin. Bioconj Chem, 15: 864-871.